ETF Holdings Breakdown of AMRX

News associated with AMRX

Assenagon Asset Management S.A. Has $6.87 Million Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Assenagon Asset Management S.A. grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 7.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 819,736 shares of the company’s stock after purchasing an additional 59,267 shares during the period. Assenagon Asset Management S.A. […] - 2025-06-15 08:43:09

California State Teachers Retirement System Acquires 12,282 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

California State Teachers Retirement System grew its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,713 shares of the company’s stock after purchasing an additional 12,282 shares during the period. […] - 2025-06-11 08:36:45

Two Sigma Advisers LP Has $347,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Two Sigma Advisers LP lessened its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 42.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,849 shares of the company’s stock after selling 32,400 shares during the quarter. Two Sigma Advisers LP’s holdings in […] - 2025-06-06 08:09:03

Squarepoint Ops LLC Increases Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Squarepoint Ops LLC grew its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 540.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 124,744 shares of the company’s stock after purchasing an additional 105,268 shares during the period. Squarepoint Ops LLC’s holdings in Amneal Pharmaceuticals were worth $988,000 as of its most recent […] - 2025-06-01 08:31:01

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 2,911 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,460 shares of the company’s stock after buying an additional […] - 2025-05-28 07:50:51

Northern Trust Corp Raises Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Northern Trust Corp increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 1,777,283 shares of the company’s stock after acquiring an additional 156,699 shares during the quarter. Northern Trust Corp’s holdings in Amneal Pharmaceuticals were worth $14,076,000 at the end of […] - 2025-05-16 07:23:00

Amneal Pharmaceuticals (NASDAQ:AMRX) Downgraded by StockNews.com to “Buy”

StockNews.com lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning. A number of other analysts also recently issued reports on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and […] - 2025-05-14 07:58:47

Price T Rowe Associates Inc. MD Raises Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Price T Rowe Associates Inc. MD boosted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 11.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 97,250 shares of the company’s stock after buying an additional 9,704 shares during the quarter. […] - 2025-05-12 08:18:52

Voya Investment Management LLC Has $384,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Voya Investment Management LLC cut its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,488 shares of the company’s stock after selling 3,442 shares during the period. Voya […] - 2025-05-11 09:06:55

Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by StockNews.com

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock. Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 […] - 2025-05-07 06:06:47

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,991,702 shares of the company’s stock after acquiring an additional 278,653 shares during the quarter. […] - 2025-05-05 08:18:54

Raymond James Financial Inc. Invests $2.95 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 371,996 shares of the company’s stock, valued at approximately $2,946,000. Several other institutional investors also recently added to or reduced […] - 2025-04-29 08:05:11

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.80 Consensus PT from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last […] - 2025-04-22 05:20:56

Wellington Management Group LLP Sells 8,577 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Wellington Management Group LLP trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.4% in the fourth quarter, HoldingsChannel reports. The firm owned 74,019 shares of the company’s stock after selling 8,577 shares during the quarter. Wellington Management Group LLP’s holdings in Amneal Pharmaceuticals were worth $586,000 as of its […] - 2025-04-15 08:32:51

Federated Hermes Inc. Purchases 5,849 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Federated Hermes Inc. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,834 shares of the company’s stock after buying an additional 5,849 shares during the period. […] - 2025-04-14 08:15:03

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership reduced its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,541,058 shares of the company’s stock after selling 527,921 shares during the […] - 2025-04-06 08:27:00

Swiss National Bank Acquires 31,900 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Swiss National Bank lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,000 shares of the company’s stock after purchasing an additional 31,900 shares during the quarter. Swiss National Bank’s […] - 2025-03-28 07:54:50

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,835 shares of the company’s stock after purchasing an additional 8,213 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $767,000 as […] - 2025-03-07 08:21:06

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $10.60

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the […] - 2025-03-05 06:55:12

Rhumbline Advisers Acquires 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Rhumbline Advisers boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 232,264 shares of the company’s stock after acquiring an additional 7,875 shares during the period. Rhumbline Advisers’ holdings in Amneal Pharmaceuticals were worth $1,840,000 as of its most recent SEC filing. […] - 2025-03-04 08:12:48

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lifted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 55.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 58,111 shares of the company’s stock after purchasing an additional 20,686 shares during the period. Y Intercept Hong Kong Ltd’s […] - 2025-03-03 08:28:58

Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Increased to Overweight at JPMorgan Chase & Co.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Marketbeat Ratings reports. The firm presently has a $12.00 price objective on the stock, up from their previous price objective of $9.00. JPMorgan […] - 2025-02-26 07:01:03

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in January

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 2,420,000 shares, a decline of 18.0% from the January 15th total of 2,950,000 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average […] - 2025-02-17 08:44:56

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average PT from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target […] - 2025-02-06 06:06:55

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires 5,523 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 46,240 shares of the company’s stock after purchasing an additional 5,523 shares […] - 2025-01-30 08:57:13

AMRX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	78,115	USD 635,075
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	12,710	USD 103,332
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	156,407	USD 1,271,589
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	156,407	USD 1,271,589
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	965	USD 7,845
Total =		404,604	USD 3,289,430

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer